Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

Glioblastoma multiforme (GBM) is at present an incurable disease with a 5-year survival rate of 5.5%, despite improvements in treatment modalities such as surgery, radiation therapy, chemotherapy [e.g., temozolomide (TMZ)], and targeted therapy [e.g., the antiangiogenic agent bevacizumab (BEV)]. Dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishri, Yossi, Vatarescu, Maayan, Luz, Ishai, Epstein, Lior, Dumančić, Mirta, Del Mare, Sara, Shai, Amit, Schmidt, Michael, Deutsch, Lisa, Den, Robert B., Kelson, Itzhak, Keisari, Yona, Arazi, Lior, Cooks, Tomer, Domankevich, Vered
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552201/
https://www.ncbi.nlm.nih.gov/pubmed/36237307
http://dx.doi.org/10.3389/fonc.2022.888100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552201/
https://www.ncbi.nlm.nih.gov/pubmed/36237307
http://dx.doi.org/10.3389/fonc.2022.888100

Ejemplares similares